As of Nov 19, 2026, 0 of 1 active firms rate FLGT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FLGT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.33 – $-0.33 · 1 analysts · -8% YoY
Next period, 1 analysts expect Fulgent Genetics Inc to earn $-0.33 a share (range $-0.33 – $-0.33), versus $-0.36 a year earlier. Full-year consensus is $-1.70, growing to $-1.36 the year after.
REVENUE · NEXT QUARTER
$89.0M
Range $89.0M – $89.0M · 1 analysts · +25% YoY
Revenue is expected to reach $89.0M (range $89.0M – $89.0M), +25.1% year-over-year. Full-year consensus is $335.1M, rising to $367.4M next year.
Top analysts covering Fulgent Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FLGT.
#1
David Westenberg
Piper Sandler · Rank #314
Neutral
$19.00-24.4% to target
Overall win rate
35%
+ Follow
#2
Andrew Cooper
Raymond James · Rank #504
Buy
$25.00-0.5% to target
Overall win rate
25%
+ Follow
#3
LL
Lu Li
UBS
Buy
$22.00-12.4% to target
Coverage
—
+ Follow
FLGT stock forecast FAQ
What is FLGT's average 12-month price target?+
The 1 active firms with a live target average $19.00 for Fulgent Genetics Inc over the next 12 months, ranging from a $19.00 high to a $19.00 low, as of Nov 19, 2026.
Is FLGT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover FLGT?+
1 active firms have a recognized rating on Fulgent Genetics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FLGT?+
Among analysts who currently cover FLGT, David Westenberg of Piper Sandler has the strongest overall Quantellect track record (Rank #314). Their current call is Neutral with a $19.00 target.
What is Fulgent Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.33 – $-0.33) across 1 analysts. Full-year EPS is projected at $-1.70, rising to $-1.36 the following year.
How much revenue is Fulgent Genetics Inc expected to report next quarter?+
Consensus revenue is $89.0M (range $89.0M – $89.0M). Full-year revenue is projected at $335.1M, growing to $367.4M next year.
Have analysts been upgrading or downgrading FLGT lately?+
As of Nov 19, 2026, 0 of 1 active firms rate FLGT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FLGT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.